## Elena Guerini-Rocco

## List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/8139395/elena-guerini-rocco-publications-by-year.pdf

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

77	1,674	20	39
papers	citations	h-index	g-index
86	2,205 ext. citations	5.2	<b>4.22</b>
ext. papers		avg, IF	L-index

#	Paper	IF	Citations
77	Hotspot ESR1 mutations are multimodal and contextual modulators of breast cancer metastasis <i>Cancer Research</i> , <b>2022</b> ,	10.1	5
76	HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast Cancer <i>Frontiers in Molecular Biosciences</i> , <b>2022</b> , 9, 834651	5.6	7
75	Low-risk triple-negative breast cancers: Clinico-pathological and molecular features <i>Critical Reviews in Oncology/Hematology</i> , <b>2022</b> , 172, 103643	7	5
74	Outcome of patients with metastatic triple negative breast cancer treated with first-line chemotherapy: a single institution retrospective analysis. <i>Breast Cancer Research and Treatment</i> , <b>2021</b> , 1	4.4	
73	Combined analysis of PTEN, HER2, and hormone receptors status: remodeling breast cancer risk profiling. <i>BMC Cancer</i> , <b>2021</b> , 21, 1152	4.8	3
72	Reliability and reproducibility among different platforms for tumour BRCA testing in ovarian cancer: a study of the Italian NGS Network. <i>Journal of Clinical Pathology</i> , <b>2021</b> , 74, 668-672	3.9	1
71	Emergency Lung Transplantation after COVID-19: Immunopathological Insights on Two Affected Patients. <i>Cells</i> , <b>2021</b> , 10,	7.9	6
70	Genomic Characterization of Concurrent Alterations in Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Mutations. <i>Cancers</i> , <b>2021</b> , 13,	6.6	4
69	Mismatch repair-deficient hormone receptor-positive breast cancers: Biology and pathological characterization. <i>Cancer Cell International</i> , <b>2021</b> , 21, 266	6.4	7
68	Immunotherapy in Breast Cancer Patients: A Focus on the Use of the Currently Available Biomarkers in Oncology. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , <b>2021</b> ,	2.2	5
67	Genomic Aberrations and Late Recurrence in Postmenopausal Women with Hormone Receptor-positive Early Breast Cancer: Results from the SOLE Trial. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 504-512	12.9	3
66	Digital Slides as an Effective Tool for Programmed Death Ligand 1 Combined Positive Score Assessment and Training: Lessons Learned from the "Programmed Death Ligand 1 Key Learning Program in Head-and-Neck Squamous Cell Carcinoma". <i>Journal of Pathology Informatics</i> , <b>2021</b> , 12, 1	4.4	7
65	The role of molecular heterogeneity targeting resistance mechanisms to lung cancer therapies. <i>Expert Review of Molecular Diagnostics</i> , <b>2021</b> , 21, 757-766	3.8	1
64	Early Breast Cancers During Pregnancy Treated With Breast-Conserving Surgery in the First Trimester of Gestation: A Feasibility Study. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 723693	5.3	0
63	Complex Differential Diagnosis between Primary Breast Cancer and Breast Metastasis from EGFR-Mutated Lung Adenocarcinoma: Case Report and Literature Review. <i>Current Oncology</i> , <b>2021</b> , 28, 3384-3392	2.8	1
62	Prospective evaluation of EBUS-TBNA specimens for programmed death-ligand 1 expression in non-small cell lung cancer patients: a pilot study. <i>Jornal Brasileiro De Pneumologia</i> , <b>2021</b> , 47, e20200584	ļ <sup>1.1</sup>	1
61	Biological and clinical features of triple negative Invasive Lobular Carcinomas of the breast. Clinical outcome and actionable molecular alterations. <i>Breast</i> , <b>2021</b> , 59, 94-101	3.6	3

60	SARS-CoV-2 detection in formalin-fixed paraffin-embedded tissue specimens from surgical resection of tongue squamous cell carcinoma. <i>Journal of Clinical Pathology</i> , <b>2020</b> , 73, 754-757	3.9	25	
59	Pharmacological management of male breast cancer. Expert Opinion on Pharmacotherapy, <b>2020</b> , 21, 149	3 <sub>‡</sub> 150	40	
58	Hereditary Gastric and Breast Cancer Syndromes Related to CDH1 Germline Mutation: A Multidisciplinary Clinical Review. <i>Cancers</i> , <b>2020</b> , 12,	6.6	18	
57	Alterations and Their Role in Cancer Management: Are We Making Headway on Precision Medicine?. <i>Genes</i> , <b>2020</b> , 11,	4.2	26	
56	Digital Pathology and PD-L1 Testing in Non Small Cell Lung Cancer: A Workshop Record. <i>Cancers</i> , <b>2020</b> , 12,	6.6	5	
55	Biological and clinical features of early triple-negative invasive lobular carcinomas of the breast <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, e12570-e12570	2.2		
54	Efficacy of Anti-PD1/PD-L1 Therapy (IO) in KRAS Mutant Non-small Cell Lung Cancer Patients: A Retrospective Analysis. <i>Anticancer Research</i> , <b>2020</b> , 40, 427-433	2.3	7	
53	Understanding EGFR heterogeneity in lung cancer. <i>ESMO Open</i> , <b>2020</b> , 5, e000919	6	17	
52	Inter-tumor genomic heterogeneity of breast cancers: comprehensive genomic profile of primary early breast cancers and relapses. <i>Breast Cancer Research</i> , <b>2020</b> , 22, 107	8.3	16	
51	Comprehensive Genomic Analysis Reveals the Prognostic Role of Copy-Number Variations in Human Malignancies. <i>Genes</i> , <b>2020</b> , 11,	4.2	2	
50	A role for the immune system in advanced laryngeal cancer. Scientific Reports, 2020, 10, 18327	4.9	6	
49	Successful treatment with avapritinib in patient with mucosal metastatic melanoma. <i>Therapeutic Advances in Medical Oncology</i> , <b>2020</b> , 12, 1758835920946158	5.4	5	
48	Next-generation sequencing-based BRCA testing on cytological specimens from ovarian cancer ascites reveals high concordance with tumour tissue analysis. <i>Journal of Clinical Pathology</i> , <b>2020</b> , 73, 168-171	3.9	7	
47	E-cadherin deregulation in breast cancer. Journal of Cellular and Molecular Medicine, 2020, 24, 5930-593	<b>6</b> 5.6	29	
46	Molecular Profile of Advanced Non-Small Cell Lung Cancers in Octogenarians: The Door to Precision Medicine in Elderly Patients. <i>Journal of Clinical Medicine</i> , <b>2019</b> , 8,	5.1	5	
45	Whole-exome sequencing and RNA sequencing analyses of acinic cell carcinomas of the breast. <i>Histopathology</i> , <b>2019</b> , 75, 931-937	7.3	9	
44	Targeting Immune-Related Biological Processes in Solid Tumors: We do Need Biomarkers. <i>International Journal of Molecular Sciences</i> , <b>2019</b> , 20,	6.3	33	
43	Tumor BRCA Test for Patients with Epithelial Ovarian Cancer: The Role of Molecular Pathology in the Era of PARP Inhibitor Therapy. <i>Cancers</i> , <b>2019</b> , 11,	6.6	11	

42	BRCA tumor test in ovarian cancers: The changing role of molecular pathology in the era of PARP inhibitor (PARPi) therapy <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 5572-5572	2.2	
41	Endocrine-responsive lobular carcinoma of the breast: features associated with risk of late distant recurrence. <i>Breast Cancer Research</i> , <b>2019</b> , 21, 153	8.3	7
40	Letter to the Editor. Clinical Lung Cancer, 2018, 19, e439-e440	4.9	3
39	Acquired Resistance to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancers: The Role of Next-Generation Sequencing on Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration Samples. <i>Archives of Pathology and Laboratory Medicine</i> , <b>2018</b> , 142, 465-473	5	4
38	Mutational analysis of triple-negative breast cancers within the International Breast Cancer Study Group (IBCSG) Trial 22-00. <i>Breast Cancer Research and Treatment</i> , <b>2018</b> , 170, 351-360	4.4	5
37	The long tail of molecular alterations in non-small cell lung cancer: a single-institution experience of next-generation sequencing in clinical molecular diagnostics. <i>Journal of Clinical Pathology</i> , <b>2018</b> , 71, 767-773	3.9	7
36	Molecular alterations and late recurrence in postmenopausal women with hormone receptor-positive node-positive breast cancer (BC): Results from the BOLEItrial <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 517-517	2.2	1
35	Lymphovascular invasion and extranodal tumour extension are risk indicators of breast cancer related lymphoedema: an observational retrospective study with long-term follow-up. <i>BMC Cancer</i> , <b>2018</b> , 18, 935	4.8	17
34	Liver toxicity in the era of immune checkpoint inhibitors: A practical approach. <i>Critical Reviews in Oncology/Hematology</i> , <b>2018</b> , 132, 125-129	7	14
33	The immune profile of EGFR-mutated non-small-cell lung cancer at disease onset and progression after tyrosine kinase inhibitors therapy. <i>Immunotherapy</i> , <b>2018</b> , 10, 1041-1045	3.8	4
32	Recurrent NAB2-STAT6 gene fusions and oestrogen receptor-Lexpression in pulmonary adenofibromas. <i>Histopathology</i> , <b>2017</b> , 70, 906-917	7.3	21
31	Targeting EGFR T790M mutation in NSCLC: From biology to evaluation and treatment. <i>Pharmacological Research</i> , <b>2017</b> , 117, 406-415	10.2	41
30	The genetic landscape of breast carcinomas with neuroendocrine differentiation. <i>Journal of Pathology</i> , <b>2017</b> , 241, 405-419	9.4	35
29	Circulating and tissue biomarkers in early-stage non-small cell lung cancer. <i>Ecancermedicalscience</i> , <b>2017</b> , 11, 717	2.7	14
28	Gene Fusion in Advanced Lung Cancer in Women: A Systematic Analysis, Review of the Literature, and Diagnostic Algorithm <i>JCO Precision Oncology</i> , <b>2017</b> , 1, 1-9	3.6	5
27	IMP3 expression in NSCLC brain metastases demonstrates its role as a prognostic factor in non-neuroendocrine phenotypes. <i>Medical Oncology</i> , <b>2017</b> , 35, 2	3.7	1
26	Multicenter Comparison of 22C3 PharmDx (Agilent) and SP263 (Ventana) Assays to Test PD-L1 Expression for NSCLC Patients to Be Treated with Immune Checkpoint Inhibitors. <i>Journal of Thoracic Oncology</i> , <b>2017</b> , 12, 1654-1663	8.9	68
25	Hibernation in Unusual Places: A Pure Typical Hibernoma of the Breast. <i>Breast Journal</i> , <b>2017</b> , 23, 104-10	051.2	1

Premalignant and Pre-invasive Lesions of the Breast 2017, 103-120 1 24 An international reproducibility study validating quantitative determination of ERBB2, ESR1, PGR, 8.3 23 20 and MKI67 mRNA in breast cancer using MammaTyper[] . Breast Cancer Research, 2017, 19, 55 Genetic analysis of microglandular adenosis and acinic cell carcinomas of the breast provides evidence for the existence of a low-grade triple-negative breast neoplasia family. Modern Pathology 22 9.8 34 , 2017, 30, 69-84 Histologically-Proven Efficacy of Bland Embolization in a Patient with Net Liver Metastasis. 21 2.7 CardioVascular and Interventional Radiology, 2016, 39, 948-52 Dramatic Antitumor Activity of Nivolumab in Advanced HER2-Positive Lung Cancer. Clinical Lung 20 4.9 4 Cancer, 2016, 17, e179-e183 The Genomic Landscape of Male Breast Cancers. Clinical Cancer Research, 2016, 22, 4045-56 85 19 12.9 Molecular profile in non-small cell lung cancers (NSCLCs) occurring in elderly.. Journal of Clinical 18 2.2 1 Oncology, **2016**, 34, 10053-10053 Molecular biomarkers in early-stage lung cancer.. Journal of Clinical Oncology, 2016, 34, e23082-e23082 2.2 17 Microglandular adenosis associated with triple-negative breast cancer is a neoplastic lesion of 16 triple-negative phenotype harbouring TP53 somatic mutations. Journal of Pathology, **2016**, 238, 677-88  $^{9\cdot4}$ 42 Rediscovering Secondary Tumors of the Prostate in the Molecular Era. Advances in Anatomic 6 5.1 Pathology, 2016, 23, 170-9 Genetic events in the progression of adenoid cystic carcinoma of the breast to high-grade 14 9.8 52 triple-negative breast cancer. Modern Pathology, 2016, 29, 1292-1305 Lobular Carcinoma in Situ: A 29-Year Longitudinal Experience Evaluating Clinicopathologic Features 2.2 13 111 and Breast Cancer Risk. Journal of Clinical Oncology, 2015, 33, 3945-52 The repertoire of somatic genetic alterations of acinic cell carcinomas of the breast: an exploratory, 12 9.4 42 hypothesis-generating study. Journal of Pathology, 2015, 237, 166-78 Are acinic cell carcinomas of the breast and salivary glands distinct diseases?. Histopathology, 2015, 11 7.3 25 67, 529-37 The Contrasting Role of p16Ink4A Patterns of Expression in Neuroendocrine and Non-Neuroendocrine Lung Tumors: A Comprehensive Analysis with Clinicopathologic and 10 3.7 11 Molecular Correlations. PLoS ONE, 2015, 10, e0144923 The birth of an adenoid cystic carcinoma. International Journal of Surgical Pathology, 2015, 23, 26-7 9 7 1.2 Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of 8 416 17.4 brain tumours than plasma. Nature Communications, 2015, 6, 8839 Small cell carcinoma of the gynecologic tract: a multifaceted spectrum of lesions. Gynecologic 64 Oncology, 2014, 134, 410-8

6	PI3K pathway activation in high-grade ductal carcinoma in situimplications for progression to invasive breast carcinoma. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 2326-37	12.9	37
5	The oncofetal protein IMP3: a useful marker to predict poor clinical outcome in neuroendocrine tumors of the lung. <i>Journal of Thoracic Oncology</i> , <b>2014</b> , 9, 1656-61	8.9	17
4	Contrast-enhanced computed tomography colonography in preoperative distinction between T1-T2 and T3-T4 staging of colon cancer. <i>Academic Radiology</i> , <b>2013</b> , 20, 590-5	4.3	17
3	HER2 in gastric cancer: a digital image analysis in pre-neoplastic, primary and metastatic lesions. <i>Modern Pathology</i> , <b>2013</b> , 26, 816-24	9.8	44
2	Schwann cell hamartoma: case report. <i>BMC Gastroenterology</i> , <b>2011</b> , 11, 68	3	19
1	Dynamic retention of Ero1alpha and Ero1beta in the endoplasmic reticulum by interactions with PDI and ERp44. <i>Antioxidants and Redox Signaling</i> , <b>2006</b> , 8, 274-82	8.4	84